Form 4: Replimune Group Director Acquires Stock Options

Sentiment:

SEC Form 4 Filing


Veleka Peeples-Dyer, a director of Replimune Group, Inc., acquired stock options for 32,000 shares on April 1, 2024.

Summary

  • On April 1, 2024, Veleka Peeples-Dyer, a director of Replimune Group, Inc., acquired stock options for 32,000 shares.
  • The exercise price of these options is $7.73 per share.
  • The options vest entirely on April 1, 2025, and expire on April 1, 2034.
  • Following the transaction, Peeples-Dyer directly owns options for 32,000 shares of Replimune common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock option grant to a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company directors. It's common for directors to receive stock options as part of their compensation.

Key Dates

DateDescription
04/01/2024Date of stock option transaction
04/01/2025Vesting date for the stock options
04/01/2034Expiration date for the stock options
04/03/2024Date of Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.